<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of dry eye in Sjögren’s disease: General principles and initial therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of dry eye in Sjögren’s disease: General principles and initial therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of dry eye in Sjögren’s disease: General principles and initial therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan N Baer, MD, MACR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Esen K Akpek, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert I Fox, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3377135"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sjögren’s disease (SjD) is a chronic multisystem inflammatory disorder characterized by impaired lacrimal and salivary gland function with resultant dryness of the eyes and mouth. A variety of other disease manifestations may also be present, including ocular or systemic extraglandular features.</p><p>The term “keratoconjunctivitis sicca” was coined by Henrik Sjögren in 1933 to describe the ocular surface disease resulting from severe aqueous tear deficiency in a series of 19 patients with concomitant dry mouth and frequent deforming arthritis [<a href="#rid1">1</a>]. This term has been largely supplanted in the medical literature by “dry eye.”</p><p>SjD may occur alone or in association with other autoimmune rheumatic conditions, including rheumatoid arthritis and systemic lupus erythematosus.</p><p>The general principles and initial treatment of dry eye in patients with SjD will be reviewed here. The treatment of dry eye in patients with moderate to severe involvement and other issues in SjD, including the clinical manifestations and diagnosis of SjD, the treatment of dry mouth and other non-ocular sicca symptoms in patients with SjD, and the treatment of extraglandular manifestations of SjD, are discussed separately. (See  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease"</a> and  <a class="medical medical_review" href="/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease"</a> and  <a class="medical medical_review" href="/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease"</a> and  <a class="medical medical_review" href="/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a> and  <a class="medical medical_review" href="/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"</a> and  <a class="medical medical_review" href="/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease"</a>.)</p><p>Dry eye unrelated to SjD and an overview of dry eye, including the clinical manifestations, diagnosis, and management of dry eye unrelated to SjD, are also presented separately. (See  <a class="medical medical_review" href="/d/html/6894.html" rel="external">"Dry eye disease"</a> and  <a class="medical medical_review" href="/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease", section on 'Dry eye and mouth in older adults'</a> and  <a class="medical medical_review" href="/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a>.)</p><p class="headingAnchor" id="H3377142"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Patients with Sjögren’s disease (SjD) benefit from multidisciplinary care. An eye care professional should evaluate and manage the dry eye of SjD patients for a number of reasons. Several tests for diagnosing and monitoring dry eye, including ocular surface staining and the tear break-up time, require a slit lamp and therefore an ophthalmological examination (see  <a class="medical medical_review" href="/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease", section on 'Tests for dry eye'</a>). In addition, <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> therapy, if prescribed for systemic manifestations of the disease, needs to be monitored at least annually for potential retinal toxicity.</p><p>Once-yearly ophthalmologic evaluations suffice for those with mild dry eye. Measuring the tear film osmolarity can be performed by non-ophthalmologists as point-of-care testing and has been reported as useful to assess presence of dry eye [<a href="#rid2">2,3</a>]. Nevertheless, some studies have questioned its diagnostic value, citing the high variability of the test in healthy subjects [<a href="#rid4">4</a>] and in patients with dry eye [<a href="#rid5">5,6</a>].</p><p>Symptoms of ocular irritation may arise from multiple causes, not only aqueous tear deficiency, and these can be differentiated by an eye care professional through slit-lamp evaluations and require specific management. Some experts thus prefer the use of the term “dysfunctional tear syndrome” [<a href="#rid7">7</a>] rather than “dry eye” to reflect the inclusion of symptomatic patients who have abnormalities in tear film stability/composition but no reduction in tear volume. Over 80 percent of patients with SjD have concomitant meibomian gland dysfunction, and this requires recognition and specific treatment [<a href="#rid8">8-10</a>]. Finally, patients with SjD and severe dry eye disease are at risk of vision-threatening ocular complications, sometimes with minimal antecedent symptoms, and regular monitoring by an eye care professional is therefore warranted [<a href="#rid11">11</a>].</p><p>The aims of therapy for dry eye are twofold: to provide relief of symptoms, including dryness, burning, a sandy-gritty ocular irritation, pain, ocular fatigue, fluctuating or diminished vision, and pressure behind the eye; and to prevent damage to the eye due to ongoing inflammation of the ocular surface, such as sterile keratitis, epithelial erosions, neovascularization and ulceration of the cornea, and scarring of the conjunctiva.</p><p>There are only a few large, well-designed, randomized trials that have evaluated the ability of specific treatments to improve dry eye signs and/or symptoms in patients with SjD. No studies have assessed the ability of any form of treatment to prevent ocular extraglandular complications such as corneal melt or sterile ulcers. A 2017 systematic literature review summarized results of available published evidence with regard to treatment outcomes [<a href="#rid12">12,13</a>]. In addition, a 2016 consensus panel provided recommendations for the evaluation and management of dry eye associated with SjD [<a href="#rid14">14</a>].</p><p>Our general approach is based upon available data from published studies as well as our clinical experience and is generally consistent with previous consensus recommendations [<a href="#rid7">7,14</a>]. The choice of therapies depends primarily upon the severity of the ocular disease, rather than whether or not there is underlying SjD. However, SjD patients need more frequent monitoring as they may not always be symptomatic with worsening of their dry eye [<a href="#rid15">15</a>]. (See <a class="local">'Initial therapy and mild disease'</a> below and <a class="local">'Moderate to severe disease'</a> below and  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease"</a>.)</p><p class="headingAnchor" id="H3377156"><span class="h1">INITIAL THERAPY AND MILD DISEASE</span><span class="headingEndMark"> — </span>Initial management in all patients should focus on symptomatic relief and restoration of tear film homeostasis. Such treatment may be sufficient in patients with mild or only episodic discomfort and in those with only mild signs of local disease, such as mild ocular surface staining or mildly increased tear osmolarity. Management includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient education regarding the disease and its complications, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Counseling regarding home, workplace, and other environmental factors that may worsen symptoms and self-management techniques for tear conservation (see <a class="local">'Tear conservation'</a> below and <a class="local">'Environmental management'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Instruction regarding the signs and symptoms of blepharitis, which are distinct from those of aqueous tear deficiency and require specific management techniques (see <a class="local">'Potential harms'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of prescription and nonprescription systemic medications that may cause or exacerbate symptoms (see <a class="local">'Avoidance of medications causing dryness'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> as needed for relief of symptoms of ocular discomfort (see <a class="local">'Artificial tears'</a> below)</p><p></p><p class="headingAnchor" id="H94900469"><span class="h2">Tear conservation</span><span class="headingEndMark"> — </span>All patients with dry eye and Sjögren’s disease (SjD) should generally adopt measures for tear conservation. The use of medications that may worsen symptoms of dryness should be avoided, whenever possible. Physical barriers, such as large-frame glasses to minimize tear evaporation, can be helpful. Video display terminal use is associated with a decreased blink rate and increased incomplete blinks, and thus may worsen dry eye when prolonged [<a href="#rid16">16-19</a>]. The same is true for other activities requiring prolonged visual attention, such as reading and driving. Frequent, short breaks and additional longer breaks from these activities may be beneficial; other proposed therapies include efforts to increase the blink rate and the increased use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>. However, the degree of benefit of these interventions for dry eye related to computer use and other forms of prolonged visual attention is uncertain [<a href="#rid19">19</a>] (see <a class="local">'Artificial tears'</a> below). The use of these strategies is widely supported by experts in dry eye and is consistent with our clinical experience [<a href="#rid7">7,20,21</a>]. However, formal study of the effectiveness of these techniques is lacking, although they have no foreseeable clinically significant risks. (See <a class="local">'Environmental management'</a> below and <a class="local">'Avoidance of medications causing dryness'</a> below and <a class="local">'Physical barriers'</a> below.)</p><p class="headingAnchor" id="H94900496"><span class="h3">Environmental management</span><span class="headingEndMark"> — </span>Exposure to environments that exacerbate dry eyes should be minimized, and preventive strategies should be employed when such avoidance is impractical. <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">Artificial tears</a> should be used regularly to help prevent complications and to increase comfort before entry into dry environments and then with increased frequency as compared with use in more humid environments. (See <a class="local">'Artificial tears'</a> below.)</p><p>The following environments may be problematic:</p><p class="bulletIndent1"><span class="glyph">●</span>Dry or windy outdoor environments</p><p class="bulletIndent1"><span class="glyph">●</span>Dry indoor environments</p><p class="bulletIndent1"><span class="glyph">●</span>Areas with polluted air and other irritants, including the presence of smokers</p><p class="bulletIndent1"><span class="glyph">●</span>Hospital operating and recovery rooms [<a href="#rid22">22</a>] (see <a class="local">'Perioperative management'</a> below)</p><p></p><p>The use of humidifiers is helpful in bedrooms and other rooms in which the patient spends a lot of time. The regular use of warm compresses over the eyes can also provide symptomatic relief by improving meibomian gland secretions.</p><p class="headingAnchor" id="H94901188"><span class="h4">Perioperative management</span><span class="headingEndMark"> — </span>An ocular lubricant should be used as a preventive measure prior to surgery. During any surgery requiring general anesthesia, it is important to prevent ocular drying by instilling an over-the-counter ocular ointment and then gently taping the eyelids shut.</p><p>In addition, patients should be allowed to bring their topical medications for dry eye from home if they are unavailable in the hospital; these medications should be available as needed.</p><p>The level of humidity in operating rooms and in postoperative units may be very low, which increases the risk of dry eye complications, including corneal abrasions. Dryness is also worsened when non-humidified oxygen is administered by facemask. (See  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease", section on 'Lubricant ointments'</a>.)</p><p>Certain ophthalmologic surgical procedures may also pose special risks. (See <a class="local">'Risks of ophthalmologic procedures'</a> below.)</p><p class="headingAnchor" id="H94900523"><span class="h3">Avoidance of medications causing dryness</span><span class="headingEndMark"> — </span>Medications used for treatment of other conditions (eg, antidepressants, antihistamines, anticholinergics, diuretics, and neuroleptics) may worsen symptoms of dryness [<a href="#rid23">23</a>], and alternatives should be sought whenever possible. The degree to which such medications are relatively contraindicated depends upon the severity of disease for which the drug is being administered and upon the amount to which the drug worsens dryness in the dose used in a given patient. The use of multiple drugs that, individually, may have modest drying effects can also be problematic.</p><p>Dryness of the eyes is often caused by the use of drugs with anticholinergic side effects, such as the tricyclic antidepressants and many others  (<a class="graphic graphic_table graphicRef100289" href="/d/graphic/100289.html" rel="external">table 1</a>) [<a href="#rid23">23</a>]. The range of medications and the adverse effects of drugs with anticholinergic activity are discussed in detail separately (see  <a class="medical medical_review" href="/d/html/3013.html" rel="external">"Drug prescribing for older adults", section on 'Anticholinergic activity'</a>). In addition, potent oral analgesics can decrease corneal sensitivity and thereby exacerbate dry eye.</p><p>Chronic use of prescription eyedrops (such as medications for glaucoma) that contain preservatives may also be bothersome for patients with SjD. Thus, dry eye patients who require these medications may need to switch to preservative-free formulations and use preservative-free <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>. (See <a class="local">'Choice of formulation'</a> below.)</p><p class="headingAnchor" id="H94900550"><span class="h3">Physical barriers</span><span class="headingEndMark"> — </span>Moisture-conserving eyewear can be employed to conserve the tear film. These may be most helpful in particular situations, such as when traveling into dry and/or windy environments such as airplanes or long air-conditioned car rides, during which humidity is low; and while exercising, especially jogging or biking, during which increased air movement on the ocular surface and decreased blink rate are encountered.</p><p>Examples of moisture-conserving eyewear include:</p><p class="bulletIndent1"><span class="glyph">●</span>Side shields, which can be fitted to glasses, reducing the evaporation rate of normal or <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a></p><p class="bulletIndent1"><span class="glyph">●</span>Wraparound sunglasses, which are more socially acceptable to many patients than goggles</p><p class="bulletIndent1"><span class="glyph">●</span>Ski or swim goggles, which also reduce evaporation</p><p></p><p>However, the use of such physical barriers is often socially unacceptable, except to more severely affected patients when other measures are insufficient and to those with frequent or persistent exposure to adverse environments.</p><p>Certain types of custom-made, large-diameter contact lenses (eg, Prosthetic Replacement of the Ocular Surface Ecosystem [PROSE]) may benefit selected patients with severe dry eye [<a href="#rid24">24</a>] but are generally not used in patients with mild disease. Bandage contact lenses facilitate symptomatic improvement but may increase the risk of corneal infection and should only be used short-term for non-healing corneal epithelial issues. Contact lenses, other than bandage lenses, should never be worn overnight (see  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease", section on 'Therapeutic contact lenses'</a>). In addition, contact lenses only protect the cornea. The conjunctiva, responsible for making the mucin layer of the tear film, is left unprotected.</p><p class="headingAnchor" id="H94901467"><span class="h2">Artificial tears</span><span class="headingEndMark"> — </span>We recommend the regular use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> in most patients with SjD, including patients with all levels of disease severity. Patients may select these from the many available tear preparations, which differ in their composition, preservatives, osmolarity, and viscosity [<a href="#rid20">20,25</a>], and which are typically available without prescription (see  <a class="drug drug_general" href="/d/drug information/8660.html" rel="external">"Artificial tears (Ophthalmic lubricants: solutions, gels, ointments): Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/8979.html" rel="external">"Hydroxypropyl methylcellulose: Drug information"</a>). Patients should try several different agents to identify the one that provides the most comfort, regardless of the theoretical advantage of the composition of one agent over another. (See <a class="local">'Artificial tear formulation'</a> below and <a class="local">'Choice of formulation'</a> below.)</p><p>The frequency of use should be guided by the need for symptomatic relief, such as reduced symptoms of irritation and improved visual acuity. <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">Artificial tears</a> may be used indefinitely; however, tears containing preservatives should generally not be used more than four times daily. Patients using other topical ocular medications (eg, for glaucoma) should switch to preservative-free alternatives whenever possible (see <a class="local">'Choice of formulation'</a> below and <a class="local">'Potential harms'</a> below). Similarly, we discourage use of preservative-free tear supplements more than eight times per day, due to a concern that this may disrupt the mucin layer and thereby aggravate the dry eye.</p><p>The use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> in patients with SjD is supported by several randomized trials that included patients with SjD and moderate to severe dry eye [<a href="#rid26">26-31</a>]. These trials showed symptomatic relief and improvements in damage to the corneal epithelium compared with baseline measurements. One compared hyaluronate and <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a> eyedrops, showing that both improved symptoms and corneal surface findings [<a href="#rid28">28</a>]. A different trial demonstrated greater benefit from hyaluronate compared with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> eye drops [<a href="#rid29">29</a>], and another trial showed greater improvement with hypotonic compared with isotonic hyaluronate [<a href="#rid26">26</a>].</p><p>Controlled trials of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> in patients with mild to moderate dry eye (not excluding SjD) have also shown therapeutic benefits [<a href="#rid32">32</a>]. In a comparison trial of artificial tears containing <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a> versus carboxymethylcellulose and hyaluronic acid in 394 dry eye patients, there was equivalent benefit in terms of improving ocular symptoms, ocular surface staining, and tear break-up times [<a href="#rid33">33</a>]. In a study of 99 dry eye patients, both lipid- and non-lipid-based artificial tears had similar benefits [<a href="#rid34">34</a>].</p><p>The trials of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> are limited by their small size and by the use of only a few selected agents. Additionally, it is unclear which of the many available preparations provides the greatest improvement and which ingredients or formulations are most effective in improving subjective and objective outcomes that are clinically important [<a href="#rid20">20,35</a>].</p><p class="headingAnchor" id="H24634482"><span class="h3">Artificial tear formulation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">Artificial tears</a> and lubricants are generally available without a prescription and may be in the form of liquid eyedrops, gels, or ointments. Gels and ointments often blur vision during use and are usually not required in patients with mild disease. However, they may be particularly useful when applied in the evening before sleep. (See  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease", section on 'Lubricant ointments'</a>.)</p><p>Typically, the major components of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> include:</p><p class="bulletIndent1"><span class="glyph">●</span>A form of cellulose (eg, hypromellose or <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a>), which is a major component of many artificial tear products, beneficial for replacement of the aqueous layer, and helps maintain viscosity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preparations containing high concentrations of sodium hyaluronate are an alternative to <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a> in artificial tear products marketed in Japan, Europe, Russia, Australia, and parts of Asia, but not the United States [<a href="#rid36">36</a>]. This naturally occurring high-molecular weight glycosaminoglycan binds water molecules and is viscoelastic, thereby improving ocular surface hydration and reducing surface friction. In the United States, there are a few topical preparations that contain low levels of sodium hyaluronate as an excipient rather than as an active ingredient [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spreading agents (eg, polyvinyl alcohol, polyethylene glycol, dextran), which are contained in many drops and which help the aqueous layer to spread over the hydrophobic corneal and conjunctival epithelium and to prevent evaporation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mucolytic agents (eg, <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">acetylcysteine</a>), which are useful in more severely affected patients when there is an overproduction of mucus that accumulates as filaments in the eye. However, an objectionable smell may limit use of these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preservatives (eg, benzalkonium, thimerosal, chlorobutanol, <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a>, polysorbate 80), which prevent bacterial contamination and which prolong shelf life. However, these may lead to local irritation and worsening of ocular surface findings. Benzalkonium is the preservative most commonly in use today, but is also the one most likely to aggravate dry eye disease through various toxic effects on the ocular surface, particularly on goblet cells [<a href="#rid38">38</a>]. Thus, the long-term and/or frequent use of tear supplements containing benzalkonium should be avoided.</p><p></p><p class="headingAnchor" id="H94901481"><span class="h3">Choice of formulation</span><span class="headingEndMark"> — </span>Patients can initially use drops containing hypromellose (0.3 percent) or <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a> (0.25 to 0.5 percent; or hyaluronic acid [0.1 to 0.18 percent], where available) as needed and up to every two to four hours (eg, Tears Naturale II, Liquifilm Tears, Liquifilm Forte, Tears Plus, Isopto Tears, and Viscotears). These drops also generally include a spreading agent and a preservative. The frequency of use varies with the degree of dryness, with the specific product used, and with the ambient humidity and other environmental factors. These tears differ in viscosity, also affecting how long they last following an application. Higher-viscosity drops require less frequent application, but they may cause visual blurring and can increase the risk of blockage of the meibomian glands, with resultant posterior blepharitis. (See  <a class="drug drug_general" href="/d/drug information/8660.html" rel="external">"Artificial tears (Ophthalmic lubricants: solutions, gels, ointments): Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/8979.html" rel="external">"Hydroxypropyl methylcellulose: Drug information"</a>.)</p><p>Preservative-free preparations (eg, Tears Naturale Free, Bion Tears, HypoTears PF, Refresh, Moisture Eyes Free, and TheraTears Free) are preferred in patients who develop irritation from frequent use of tears containing preservatives. The irritation related to preservatives can be associated with ocular surface changes involving the cornea and conjunctiva, with abnormal tear film, and with inflammation [<a href="#rid39">39</a>]. Such irritation may occur with use every two to four hours in some patients; thus, patients should generally avoid using drops containing preservatives more than four times daily. Preservative-free tears are typically supplied in single-use dispensers/vials. Potential disadvantages of these fluids are high cost and, for patients with arthritis, difficulty with opening the single-use containers. These products may be available for purchase in bulk at lower cost through the internet.</p><p>The benefits of switching from preserved to preservative-free formulations have not been formally evaluated in patients with SjD but have been shown in both retrospective and prospective studies of patients being treated for glaucoma, in whom substantial reductions in irritation symptoms and in signs of meibomian gland dysfunction and conjunctival and corneal damage were seen with reduced usage of preservative-containing drops, particularly after switching entirely to preservative-free drops [<a href="#rid39">39-42</a>]. In one prospective study involving 158 patients, the number of patients with symptoms during treatment was reduced by half after switching to preservative-free medication, and the number of patients with abnormal signs was reduced by 30 to 50 percent [<a href="#rid42">42</a>]. As examples, symptoms of irritation, burning, and stinging and findings of corneal <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">fluorescein</a> staining were both reduced after 6 and 12 weeks with preservative-free drops (from 56 to 31 to 28 percent and from 82 to 53 to 41 percent, respectively).</p><p>There are additional differences in individual preparations [<a href="#rid20">20,43</a>]. An example of a tear that has a decreased osmolarity to compensate for higher salt concentrations in the dry eye is HypoTears. Systane drops include a lipid-stabilizing agent. The addition of a mucolytic such as <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">acetylcysteine</a>, which breaks up mucus strands and filaments, should be tried in patients who complain of sticky eyes in the morning or who have mucus filaments on examination. The patient should be warned of its unpleasant smell (like rotten eggs) [<a href="#rid44">44</a>].</p><p>Slow-release artificial tear inserts (eg, Lacrisert), which contain <a class="drug drug_general" data-topicid="8978" href="/d/drug information/8978.html" rel="external">hydroxypropyl cellulose</a> but no preservatives, avoid the need for frequent instillation of drops (see  <a class="drug drug_general" href="/d/drug information/8978.html" rel="external">"Hydroxypropyl cellulose: Drug information"</a>). However, artificial tear inserts are difficult for many patients with arthritis to place in the lower conjunctival recess. The patient must have enough tears to dissolve the pellet and enough dexterity to place the insert into the eye without damage to the corneal surface. These inserts are usually reserved for bedtime use, since they invariably blur the vision.</p><p class="headingAnchor" id="H94901495"><span class="h3">Potential harms</span><span class="headingEndMark"> — </span>There are several problems that can be associated with the use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>, including irritation due to components of the drops themselves and blepharitis.</p><p class="bulletIndent1"><span class="glyph">●</span>Itching or increased irritation of the eye may occur in some patients with use of drops that contain preservatives, stabilizers, or solubilizers [<a href="#rid39">39</a>]. A preservative that is acceptable to most patients without severe dry eyes may reach a higher concentration in the patient with dry eyes and may be more likely to cause problems. Although these additives extend the lifetime of products, they may produce local irritation and persistent symptoms despite the use of drops, especially if used every two to four hours. If this occurs, an alternative preparation can be tried that is preservative-free or uses a different preservative. The preservatives used in <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> that are most responsible for irritation in dry eye patients (eg, benzalkonium chloride) have generally been replaced by less irritating compounds but may still be used in other types of eye drops.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posterior blepharitis is caused by clogging, inflammation and subclinical infection (commonly staphylococcal) of the meibomian glands of the eyelid; it can be worsened by contact lens use. Symptoms resemble those of aqueous tear deficiency, but, unlike aqueous tear deficiency, blepharitis is often associated with redness of the lower lids, sometimes excessive tearing, and clogged-up meibomian gland orifices with lid margin telangiectasia. It is important to evaluate the presence of blepharitis in patients with SjD and address it separately from aqueous tear deficiency. The evaluation and treatment of blepharitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/6915.html" rel="external">"Blepharitis"</a>.)</p><p></p><p class="headingAnchor" id="H3377163"><span class="h1">MODERATE TO SEVERE DISEASE</span><span class="headingEndMark"> — </span>Treatment of moderate to severe disease is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease"</a>.)</p><p>Briefly, the treatment of such patients includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate disease</strong> – In patients with moderate episodic or chronic symptoms or with signs of disease such as variable corneal staining, mild debris, or an abnormal Schirmer test, additional measures and some changes in topical therapies are usually required while continuing initial preventive measures. These interventions may include more frequent and preservative-free <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>, lubricating ointment at night, topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="109082" href="/d/drug information/109082.html" rel="external">lifitegrast</a>, topical steroids, punctal plugging, and other interventions. Patients with dry mouth as well may also be treated with an oral secretagogue, such as <a class="drug drug_general" data-topicid="9772" href="/d/drug information/9772.html" rel="external">pilocarpine</a> or <a class="drug drug_general" data-topicid="8884" href="/d/drug information/8884.html" rel="external">cevimeline</a>. (See <a class="local">'Initial therapy and mild disease'</a> above and  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease", section on 'Moderate disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe disease</strong> – Patients with severe disease, signs of which may include marked or severe punctate corneal erosions, filamentary keratitis, and conjunctival vital dye staining, may require intensification of therapies already being employed or additional interventions, including those used for moderate disease symptoms or signs, moisture goggles or other physical barriers for tear conservation, permanent punctal occlusion, systemic antiinflammatory and immunosuppressive therapies, and other interventions. (See <a class="local">'Initial therapy and mild disease'</a> above and  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease", section on 'Moderate disease'</a> and  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease", section on 'Severe disease'</a>.)</p><p></p><p class="headingAnchor" id="H3377289"><span class="h1">RISKS OF OPHTHALMOLOGIC PROCEDURES</span><span class="headingEndMark"> — </span>Patients with Sjögren’s disease (SjD) may be at increased risk compared with the general population if they undergo certain ophthalmologic procedures, including keratoplasty and blepharoplasty.</p><p>Treatment of refractive errors by laser such as LASIK or PRK is contraindicated in patients with SjD. Such procedures may exacerbate preexisting dryness and may lead to corneal melt in patients with SjD [<a href="#rid45">45-47</a>].</p><p>Surgeons performing blepharoplasty should be aware of the dry eye syndrome, since elective surgery on the eyelids can mechanically alter the anatomy sufficiently to aggravate a subclinical condition, resulting in full-blown dry eye. This may occur due to interruption of the neural innervations as well as anatomical abnormalities due to inadequate closure and blink leading to excessive evaporation of the tear film [<a href="#rid48">48-51</a>].</p><p>Other more common procedures, such as cataract surgery, should be deferred until improvement of the ocular surface and tear film parameters has been achieved [<a href="#rid52">52,53</a>]. In addition, the use of topical nonsteroidal antiinflammatory medications following cataract surgery in patients with significant dry eye, particularly in the setting of SjD, can lead to non-healing ulcers or sterile keratolysis and is thus contraindicated [<a href="#rid54">54-56</a>].</p><p class="headingAnchor" id="H640464401"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117117.html" rel="external">"Society guideline links: Sjögren's disease"</a>.)</p><p class="headingAnchor" id="H3377304"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/85725.html" rel="external">"Patient education: Sjögren's disease (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/580.html" rel="external">"Patient education: Sjögren's disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3377311"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Several approaches should be used to treat dry eye in patients with Sjögren’s disease (SjD). Attention to ambient humidity and other environmental factors, attention to medications that exacerbate dryness that are being used for other indications, and use of physical barriers to avoid drying or irritation of the eyes are important first-line measures. Particular attention to ocular exposure and care should be given to patients undergoing surgical procedures. (See <a class="local">'Tear conservation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with SjD, we recommend the regular use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> as needed rather than the use of interventions for tear conservation alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Identifying the agent that provides the most comfort for an individual patient is best determined by trying different agents. At night, a longer-acting lubricant ointment may be useful. (See <a class="local">'Artificial tears'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with increased irritation of the eye with use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> containing preservatives, stabilizers, or solubilizers, and in patients requiring artificial tears and other topical ocular medications containing preservatives more than four times daily, an alternative preparation should be tried that is preservative-free or contains a different preservative. (See <a class="local">'Artificial tears'</a> above and <a class="local">'Choice of formulation'</a> above and <a class="local">'Potential harms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blepharitis may complicate SjD, and increased ocular irritation from lid margin inflammation and infection may be misinterpreted as an inadequate response to therapies. It is important to differentiate from aqueous tear deficiency because it requires separate treatment rather than intensification of ocular lubricant therapy. Blepharitis is often associated with redness of the eyelids, episodes of excessive tearing, and evidence of meibomian gland plugging and telangiectasia. Blepharitis can be improved with warm compresses with or without topical/oral antibiotics. (See <a class="local">'Potential harms'</a> above and  <a class="medical medical_review" href="/d/html/6915.html" rel="external">"Blepharitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SjD may be at increased risk compared with the general population if they undergo certain ophthalmologic procedures, including keratoplasty and blepharoplasty. Treatment of refractive errors by laser such as LASIK or PRK is contraindicated in patients with SjD. Surgeons performing blepharoplasty should be aware of the dry eye syndrome, since elective surgery on the eyelids can aggravate subclinical disease and markedly worsen dry eye. (See <a class="local">'Risks of ophthalmologic procedures'</a> above.)</p><p></p><p class="headingAnchor" id="H1651249626"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Creamer, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sjögren H. Zur Kenntnis der Keratoconjunctivitis sicca. Keratitis filiformis bei Hypofunktion der Tränendrüsen. Acta Ophthalmol (Copenh) 1933; 1:151.</a></li><li><a class="nounderline abstract_t">Utine CA, Bıçakçıgil M, Yavuz S, Çiftçi F. Tear osmolarity measurements in dry eye related to primary Sjögren's syndrome. Curr Eye Res 2011; 36:683.</a></li><li><a class="nounderline abstract_t">Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792.</a></li><li><a class="nounderline abstract_t">Baenninger PB, Voegeli S, Bachmann LM, et al. Variability of Tear Osmolarity Measurements With a Point-of-Care System in Healthy Subjects-Systematic Review. Cornea 2018; 37:938.</a></li><li><a class="nounderline abstract_t">Szalai E, Berta A, Szekanecz Z, et al. Evaluation of tear osmolarity in non-Sjögren and Sjögren syndrome dry eye patients with the TearLab system. Cornea 2012; 31:867.</a></li><li><a class="nounderline abstract_t">Bunya VY, Fuerst NM, Pistilli M, et al. Variability of Tear Osmolarity in Patients With Dry Eye. JAMA Ophthalmol 2015; 133:662.</a></li><li><a class="nounderline abstract_t">Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900.</a></li><li><a class="nounderline abstract_t">Shimazaki J, Goto E, Ono M, et al. Meibomian gland dysfunction in patients with Sjögren syndrome. Ophthalmology 1998; 105:1485.</a></li><li><a class="nounderline abstract_t">Akpek EK, Klimava A, Thorne JE, et al. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea 2009; 28:493.</a></li><li><a class="nounderline abstract_t">Sullivan DA, Dana R, Sullivan RM, et al. Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome. Ophthalmic Res 2018; 59:193.</a></li><li><a class="nounderline abstract_t">Akpek EK, Mathews P, Hahn S, et al. Ocular and systemic morbidity in a longitudinal cohort of Sjögren's syndrome. Ophthalmology 2015; 122:56.</a></li><li><a class="nounderline abstract_t">Akpek EK, Lindsley KB, Adyanthaya RS, et al. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review. Ophthalmology 2011; 118:1242.</a></li><li><a class="nounderline abstract_t">Shih KC, Lun CN, Jhanji V, et al. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (Lond) 2017; 14:26.</a></li><li><a class="nounderline abstract_t">Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf 2015; 13:118.</a></li><li><a class="nounderline abstract_t">Adatia FA, Michaeli-Cohen A, Naor J, et al. Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome. Can J Ophthalmol 2004; 39:767.</a></li><li><a class="nounderline abstract_t">Wolkoff P, Nøjgaard JK, Franck C, Skov P. The modern office environment desiccates the eyes? Indoor Air 2006; 16:258.</a></li><li><a class="nounderline abstract_t">Hagan S, Lory B. Prevalence of dry eye among computer users. Optom Vis Sci 1998; 75:712.</a></li><li><a class="nounderline abstract_t">Blehm C, Vishnu S, Khattak A, et al. Computer vision syndrome: a review. Surv Ophthalmol 2005; 50:253.</a></li><li><a class="nounderline abstract_t">Kamøy B, Magno M, Nøland ST, et al. Video display terminal use and dry eye: preventive measures and future perspectives. Acta Ophthalmol 2022; 100:723.</a></li><li><a class="nounderline abstract_t">Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:163.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012; 8:399.</a></li><li><a class="nounderline abstract_t">Yu HD, Chou AH, Yang MW, Chang CJ. An analysis of perioperative eye injuries after nonocular surgery. Acta Anaesthesiol Taiwan 2010; 48:122.</a></li><li><a class="nounderline abstract_t">Fraunfelder FT, Sciubba JJ, Mathers WD. The role of medications in causing dry eye. J Ophthalmol 2012; 2012:285851.</a></li><li><a class="nounderline abstract_t">Dimit R, Gire A, Pflugfelder SC, Bergmanson JP. Patient ocular conditions and clinical outcomes using a PROSE scleral device. Cont Lens Anterior Eye 2013; 36:159.</a></li><li><a class="nounderline abstract_t">Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci 2020; 24:8642.</a></li><li><a class="nounderline abstract_t">Aragona P, Di Stefano G, Ferreri F, et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients. Br J Ophthalmol 2002; 86:879.</a></li><li><a class="nounderline abstract_t">Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002; 86:181.</a></li><li><a class="nounderline abstract_t">Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol 2005; 243:531.</a></li><li><a class="nounderline abstract_t">Condon PI, McEwen CG, Wright M, et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol 1999; 83:1121.</a></li><li><a class="nounderline abstract_t">McDonald CC, Kaye SB, Figueiredo FC, et al. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond) 2002; 16:601.</a></li><li><a class="nounderline abstract_t">Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome. Cornea 1996; 15:120.</a></li><li><a class="nounderline abstract_t">van der Westhuizen L, Pucker AD. Over the counter (OTC) artificial tear drops for dry eye syndrome: A Cochrane review summary. Int J Nurs Stud 2017; 71:153.</a></li><li><a class="nounderline abstract_t">Aragona P, Benítez-Del-Castillo JM, Coroneo MT, et al. Safety and Efficacy of a Preservative-Free Artificial Tear Containing Carboxymethylcellulose and Hyaluronic Acid for Dry Eye Disease: A Randomized, Controlled, Multicenter 3-Month Study. Clin Ophthalmol 2020; 14:2951.</a></li><li><a class="nounderline abstract_t">Craig JP, Muntz A, Wang MTM, et al. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. Ocul Surf 2021; 20:62.</a></li><li><a class="nounderline abstract_t">Pucker A, Marrone M, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev 2012; :CD009729.</a></li><li><a class="nounderline abstract_t">Abelson MB, Ousler G, Smith L, Santanam U. Bring them to tears with your treatment. Rev Ophthalmol 2015.</a></li><li><a class="nounderline abstract_t">Kathuria A, Shamloo K, Jhanji V, Sharma A. Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf 2017; 15:511.</a></li><li><a class="nounderline abstract_t">Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29:312.</a></li><li><a class="nounderline abstract_t">Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418.</a></li><li><a class="nounderline abstract_t">Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.</a></li><li><a class="nounderline abstract_t">Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010; 88:329.</a></li><li><a class="nounderline abstract_t">Foulks GN. Treatment of dry eye disease by the non-ophthalmologist. Rheum Dis Clin North Am 2008; 34:987.</a></li><li><a class="nounderline abstract_t">Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 1984; 14:77.</a></li><li><a class="nounderline abstract_t">Campos M, Takahashi R, Tanaka H, et al. Inflammation-related scarring after photorefractive keratectomy. Cornea 1998; 17:607.</a></li><li><a class="nounderline abstract_t">Di Pascuale MA, Liu TS, Trattler W, Tseng SC. Lipid tear deficiency in persistent dry eye after laser in situ keratomileusis and treatment results of new eye-warming device. J Cataract Refract Surg 2005; 31:1741.</a></li><li><a class="nounderline abstract_t">Albietz JM, Lenton LM, McLennan SG. Dry eye after LASIK: comparison of outcomes for Asian and Caucasian eyes. Clin Exp Optom 2005; 88:89.</a></li><li><a class="nounderline abstract_t">Graham WP 3rd, Messner KH, Miller SH. Keratoconjunctivitis sicca symptoms appearing after blepharoplasty. The "dry eye" syndrome. Plast Reconstr Surg 1976; 57:57.</a></li><li><a class="nounderline abstract_t">Rees TD, Jelks GW. Blepharoplasty and the dry eye syndrome: guidelines for surgery? Plast Reconstr Surg 1981; 68:249.</a></li><li><a class="nounderline abstract_t">Rees TD, LaTrenta GS. The role of the Schirmer's test and orbital morphology in predicting dry-eye syndrome after blepharoplasty. Plast Reconstr Surg 1988; 82:619.</a></li><li><a class="nounderline abstract_t">Saadat D, Dresner SC. Safety of blepharoplasty in patients with preoperative dry eyes. Arch Facial Plast Surg 2004; 6:101.</a></li><li><a class="nounderline abstract_t">Donthineni PR, Das AV, Shanbhag SS, Basu S. Cataract Surgery in Dry Eye Disease: Visual Outcomes and Complications. Front Med (Lausanne) 2020; 7:575834.</a></li><li><a class="nounderline abstract_t">Ram J, Gupta A, Brar G, et al. Outcomes of phacoemulsification in patients with dry eye. J Cataract Refract Surg 2002; 28:1386.</a></li><li><a class="nounderline abstract_t">Cohen KL. Sterile corneal perforation after cataract surgery in Sjögren's syndrome. Br J Ophthalmol 1982; 66:179.</a></li><li><a class="nounderline abstract_t">Ting DSJ, Ghosh S. Acute corneal perforation 1 week following uncomplicated cataract surgery: the implication of undiagnosed dry eye disease and topical NSAIDs. Ther Adv Ophthalmol 2019; 11:2515841419869508.</a></li><li><a class="nounderline abstract_t">Harada K, Mohamed YH, Uematsu M, et al. Three cases of acute sterile corneal melt after cataract surgery. Am J Ophthalmol Case Rep 2019; 13:62.</a></li></ol></div><div id="topicVersionRevision">Topic 14922 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Zur Kenntnis der Keratoconjunctivitis sicca. Keratitis filiformis bei Hypofunktion der Tränendrüsen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21780917" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tear osmolarity measurements in dry eye related to primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310379" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tear osmolarity in the diagnosis and management of dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620566" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Variability of Tear Osmolarity Measurements With a Point-of-Care System in Healthy Subjects-Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22580437" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluation of tear osmolarity in non-Sjögren and Sjögren syndrome dry eye patients with the TearLab system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25811641" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Variability of Tear Osmolarity in Patients With Dry Eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17102664" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dysfunctional tear syndrome: a Delphi approach to treatment recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709762" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Meibomian gland dysfunction in patients with Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19421051" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation of patients with dry eye for presence of underlying Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29627826" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178806" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ocular and systemic morbidity in a longitudinal cohort of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459453" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of Sjögren's syndrome-associated dry eye an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29200970" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25881996" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical guidelines for management of dry eye associated with Sjögren disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696767" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16842606" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The modern office environment desiccates the eyes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9798209" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence of dry eye among computer users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15850814" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Computer vision syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35122403" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Video display terminal use and dry eye: preventive measures and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17508120" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22549247" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Topical and systemic medications for the treatment of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864060" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An analysis of perioperative eye injuries after nonocular surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23050121" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The role of medications in causing dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499361" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Patient ocular conditions and clinical outcomes using a PROSE scleral device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32964952" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12140209" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815344" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965673" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502570" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12194076" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8925658" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28237389" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Over the counter (OTC) artificial tear drops for dry eye syndrome: A Cochrane review summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33061281" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety and Efficacy of a Preservative-Free Artificial Tear Containing Carboxymethylcellulose and Hyaluronic Acid for Dry Eye Disease: A Randomized, Controlled, Multicenter 3-Month Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33401019" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Over the counter (OTC) artificial tear drops for dry eye syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bring them to tears with your treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33800965" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736341" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : TFOS DEWS II iatrogenic report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20302969" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Preservatives in eyedrops: the good, the bad and the ugly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11914211" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534814" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ocular symptoms and signs with preserved and preservative-free glaucoma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20546237" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984417" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of dry eye disease by the non-ophthalmologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6399627" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Primary Sjogren syndrome: clinical and immunopathologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820940" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Inflammation-related scarring after photorefractive keratectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246778" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lipid tear deficiency in persistent dry eye after laser in situ keratomileusis and treatment results of new eye-warming device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807640" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dry eye after LASIK: comparison of outcomes for Asian and Caucasian eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1244611" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Keratoconjunctivitis sicca symptoms appearing after blepharoplasty. The "dry eye" syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7255588" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Blepharoplasty and the dry eye syndrome: guidelines for surgery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3420183" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The role of the Schirmer's test and orbital morphology in predicting dry-eye syndrome after blepharoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023797" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety of blepharoplasty in patients with preoperative dry eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33117835" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cataract Surgery in Dry Eye Disease: Visual Outcomes and Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12160808" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcomes of phacoemulsification in patients with dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7066269" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sterile corneal perforation after cataract surgery in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31448362" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute corneal perforation 1 week following uncomplicated cataract surgery: the implication of undiagnosed dry eye disease and topical NSAIDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30582074" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Three cases of acute sterile corneal melt after cataract surgery.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
